fda compounding semaglutide enforcement november 2025 news Diabetes advocacy group discourages use of compounded GLP-1 drugs Drug compounders sue FDA over

Sophie M.

Cell Metab 8(3):237248

KRAS mutant cancer cell lines (HCT116 and Panc-1) were more sensitive to GSTO1 inhibition (Supplementary Table 25)

News-Medical+3EurekAlert!+3ASMBS+3 To put numbers on it: Surgical patients lost ~58 lbs in two years ( 24% of total body weight, or TBW) GLP-1 patients lost only ~12 lbs ( 4.7% TBW) over the same period EurekAlert!+2News-Medical+2 Even among GLP-1 users who continued therapy for a full year, weight loss averaged only ~7% TBWstill far less than surgical outcomes EurekAlert!+2ASMBS+2 Another rigorous analysis published in JAMA Surgery compared weight loss surgery and GLP-1 receptor agonists over two years

The goal isnt just short-term loss but sustainable health improvement

The support team is trained to handle both technical and health-related queries, ensuring a seamless experience from purchase to usage.